Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Amgen

Clinicaltrial registered6 Nov 2026

Amgen

6 Nov 2026: Trial registered · Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations After Multiple Doses. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
6 Nov 2026
Title
Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations After Multiple Doses
Conditions
Obesity, Overweight
Phase
Phase 1
Study Type
Interventional
Status
Not Yet Recruiting
Reference
NCT07921316
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Amgen

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for Amgen in our registers.

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.